Gilead Sciences (GILD) is acquiring LEO Pharma's STAT6 program for the potential treatment of patients with inflammatory diseases for up to $1.7 billion, including an upfront payment of $250 million, as part of a partnership agreement, the companies said Saturday.
Under the terms of the deal, Gilead will acquire LEO Pharma's STAT6 small molecule inhibitors and targeted protein degraders and lead development efforts for oral products, while LEO Pharma will lead development for potential topical applications.
In addition to the payments, LEO Pharma may also receive tiered royalties of high single-digit to mid-teens on sales of oral STAT6 products while Gilead may receive similar tiered royalties on sales of topical STAT6 products.
The transaction with LEO Pharma is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by about $0.15 to $0.17, the companies said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。